Filipa Alexandre, Ana
Stoelzel, Matthias
Kiran, Amit
Garcia-Hernandez, Alberto
Morga, Antonia
Kalra, Philip A.
Funding for this research was provided by:
Astellas Pharma, Inc.
Article History
Received: 29 August 2022
Accepted: 13 March 2023
First Online: 8 June 2023
Declarations
:
: AK, AM, and MS are employees of Astellas Pharma Europe Ltd. AFA was an employee of Astellas Pharma Europe Ltd. at the time of the study. AGH reports no conflicts of interest. PAK is the principal investigator of the Salford Kidney Study, and reports grants or contracts to his institution from Astellas Pharma, Inc., Vifor, Evotec, Pharmacosmos, and Unicyte; consulting fees from Astra Zeneca, Vifor, Unicyte, and UCB; honoraria from Vifor, AstraZeneca, Pfizer, Pharmacosmos, Napp, and Bayer; support for attending meetings/travel from Pharmacosmos and Vifor; and Advisory Board participation for Sanofi, Vifor, and Novartis; Astellas provided a grant to support data extraction which enabled the Salford Kidney Study analyses reported in this manuscript.
: The Salford Kidney Study complies with the Helsinki Declaration, and ethical approval was granted by the North West-Greater Manchester South Ethics committee (15/NW/0818).
: This study did not include animal research.
: Patients are enrolled in the SKS after written informed consent is obtained.